Patent · US Active

Antisense antiviral compound and method for treating ssRNA viral infection

US8906872B2 · kind B2 · utility

36Cited by

45References

22Claims

0Family size

Assignee

Sarepta Therapeutics, Inc. · US

Inventors

Patrick L. Iversen · Corvallis, US
David A. Stein · Corvallis, US
Dwight D. Weller · Corvallis, US

Key dates

Filing date	Dec 22, 2011
Grant date	Dec 9, 2014
Priority date	—
Expiry date	Dec 22, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Flaviviridae, Picornoviridae, Caliciviridae, Togaviridae, Arteriviridae, Coronaviridae, Astroviridae and Hepeviridae families in the treatment of a viral infection. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having a sequence of 12-40 subunits, including at least 12 subunits having a targeting sequence that is complementary to a region associated with stem-loop secondary structure within the 5′-terminal end 40 bases of the positive-sense RNA strand of the virus.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.